Hi I announce this news a little earlier than planned. The initial results are in and its not what we expected!Surprised, Disappointed. Indeed. But the Work Continues......I'm very surprised and as you can imagine, as a founder hopeful to be doing...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

CEO Justin Hanka provides update on Phase 2B clinical trials.

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4